Theolytics appoints David Apelian as CEO

Oxford, UK-based clinical-stage biotech Theolytics today announced the appointment of biotechnology industry leader David Apelian as chief executive (CEO).

Dr Apelian brings 25 years of leadership experience in both start-up and public biotechnology companies. He has worked across all phases of drug development, from discovery to registration, and has expertise in multiple therapeutic areas, including immune-oncology, therapeutic cancer vaccines, infectious diseases and rare diseases.

“David brings significant depth and breadth of strategic and operational leadership to Theolytics, combined with a wealth of clinical development and regulatory experience. This will be of great benefit as the company executes its clinical development programmes, including the ongoing Phase I/IIa clinical trial of THEO-260 in ovarian cancer,” Theolytics’ executive chairman Mike Grey, adding: “The Theolytics board is delighted that David has joined us in this role and is confident in his ability to build on the key milestones achieved by the founding team.”